Search

Retatrutide and Tirzepatide pre-blended for advanced metabolic protocols. Dual and triple agonist coverage in one vial.

Triple incretin agonist activating GLP-1, GIP, and glucagon receptors. The most comprehensive metabolic receptor coverage in a single peptide.

FDA logged roughly 3,900 public comments by the July 30, 2026 deadline on whether GLP-1 bulk substances belong on the 503B bulks list—one of the agency's busiest compounding dockets ever.

Eli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.

ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.

Product Type:Weight Management PeptideCOA Specification: 15mg per vialShort Introduction:Retatrutide is a powerful triple receptor agonist designed for effective weight management. It suppresses appetite, boosts metabolism and regulates blood sugar levels, helping users reduce body fat and maintain

Product Type:Weight Management PeptideCOA Specification: 10mg per vialShort Introduction:Retatrutide 10mg is a potent triple receptor agonist for professional weight management. It curbs cravings, accelerates metabolism and stabilizes blood glucose, supporting continuous fat loss and body contouring

Product Type:Weight Management PeptideCOA Specification: 5mg per vialShort Introduction:Retatrutide 5mg is a powerful triple receptor agonist designed for effective weight management. It suppresses appetite, boosts metabolism and regulates blood sugar levels, helping users reduce body fat and mainta